



Sleep Disorder Agents – Hetlioz (tasimelteon)

Please provide the information below, please print your answer, attach supporting documentation, sign, date, and return to our office as soon as possible to expedite this request.

Please FAX responses to: (800) 869-7791. Phone: (855) 322-4082.

Apple Health Preferred Drug List: <https://www.hca.wa.gov/assets/billers-and-providers/apple-health-preferred-drug-list.xlsx>

Date of request:			
Patient	Date of birth	Molina ID	
Pharmacy name	Pharmacy NPI	Telephone number	Fax number
Prescriber	Prescriber NPI	Telephone number	Fax number
Medication and strength		Directions for use	Qty/Days supply
<p>1. Is this request for a continuation of existing therapy? <input type="checkbox"/> Yes <input type="checkbox"/> No If yes, is there documentation of a positive clinical response from baseline [e.g., improved sleep quality, decreased nighttime awakening, increased sleep time, maintain regular or improved sleep intervals]? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>2. Indicate patient's diagnosis: <input type="checkbox"/> Non-24-Hour Sleep-Wake Disorder (N24SWD) in adults <input type="checkbox"/> Nighttime sleep disturbances in Smith-Magenis Syndrome (SMS) <input type="checkbox"/> Other. Specify: _____</p> <p>3. Is this prescribed by or in consultation with a psychiatrist, neurologist, or sleep specialist? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>For diagnosis of Non-24-Hour Sleep-Wake Disorder (N24SWD) in adults:</p> <p>4. Does patient have any of the following (check all that apply): <input type="checkbox"/> History of insomnia or excessive daytime sleepiness alternating with asymptomatic episodes <input type="checkbox"/> Symptoms have persisted for at least 3 months <input type="checkbox"/> Documentation of gradually shifting sleep-wake times demonstrated by daily sleep logs or actigraphy for at least 14 consecutive days</p> <p>5. Is the patient blind in both eyes without light perception? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>For diagnosis of Nighttime sleep disturbances in Smith-Magenis Syndrome (SMS):</p> <p>6. Has patient's diagnosis of SMS been confirmed by one of the following? <input type="checkbox"/> A heterozygous deletion of RAI1 on chromosome 17p11.2 <input type="checkbox"/> Presence of a pathogenic variant involving RAI1 on chromosome 17p11.2</p> <p>7. Does the patient have documentation of sleep disturbances (e.g frequent nocturnal arousals, early morning awakenings, daytime sleep attacks, inability to fall asleep)? <input type="checkbox"/> Yes <input type="checkbox"/> No</p>			

8. Does the patient have a history of failure contraindication, or intolerance to the following: (check all that apply)

A beta-1 selective blocker (e.g., acebutolol)

Specify drug: _____

An additional medication used to promote sleep (e.g., ramelteon, clonidine, trazodone, diphenhydramine etc.) Specify drug: _____

REQUIRED WITH THIS REQUEST

Chart notes

For SMS:

- Diagnostic testing
- Documentation of sleep disturbance

For N24SWD:

- Sleep logs or actigraphy if applicable

Prescriber signature

Prescriber specialty

Date